[1]周静文,何明基,练 辉,等.免疫检查点抑制剂PD- 1免疫相关不良反应的临床分析[J].介入放射学杂志,2021,30(01):29-33.
 ZHOU Jingwen,HE Mingji,LIAN Hui,et al.Clinical analysis of immune-related adverse events of PD-1 immune checkpoint inhibitors[J].journal interventional radiology,2021,30(01):29-33.
点击复制

免疫检查点抑制剂PD- 1免疫相关不良反应的临床分析()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年01
页码:
29-33
栏目:
肿瘤介入
出版日期:
2021-01-25

文章信息/Info

Title:
Clinical analysis of immune-related adverse events of PD-1 immune checkpoint inhibitors
作者:
周静文 何明基 练 辉 黄文薮 黄敬君 郭永建 蔡明岳 朱康顺
Author(s):
ZHOU Jingwen HE Mingji LIAN Hui HUANG Wensou HUANG Jingjun GUO Yongjian CAI Mingyue ZHU Kangshun.
Department of Interventional Radiology, Affiliated Second Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province 510260, China
关键词:
【关键词】 PD-1 免疫检查点抑制剂 不良反应
文献标志码:
A
摘要:
【摘要】 目的 探讨程序性细胞死亡蛋白-1(PD-1)免疫检查点抑制剂(ICI)临床应用中的免疫相关不良反应(irAE)及临床处理。方法 回顾性分析自2019年1月至12月共194例/473次接受PD-1治疗恶性肿瘤的患者,观察治疗期间患者发生的irAE,包括不良反应的类别、分级、发生时间、持续时间、处理方案、预后等指标。结果 194例患者中,83例发生irAE,发生率为42.8%,其中13例(6.7%)同时出现累及多个系统的不良反应。发生的不良反应中1、2级不良反应75例(38.7%),3级以上不良反应8例(4.1%),3级以上不良反应分别为3级肝毒性3例、3级结肠炎1例、3级皮肤毒性2例、4级肺炎1例、5级肺炎死亡1例。7例患者经激素冲击治疗、维持治疗和对症治疗后不良反应完全缓解,其中5例继续使用PD-1单抗、2例停用,1例患者因免疫性肺炎观察延迟导致全身多器官功能衰竭死亡。irAE发生在不同系统或器官的发生时间、持续时间各有不同。结论 PD-1在临床应用中是安全的,3级以上不良反应发生率低,及时发现、早期激素治疗有效。

参考文献/References:

[1] Couzin- Frankel J. Breakthrough of the year 2013. Cancer immunotherapy[J]. Science, 2013, 342: 1432- 1433.
[2] Postow MA,Callahan MK,Wolchok JD. Immune checkpoint blockade in cancer therapy[J]. J Clin Oncol, 2015, 33:1974- 1982.
[3] Friedman CF, Proverbs- Singh TA, Postow MA. Treatment of the immune- related adverse effects of immune checkpoint inhibitors: a review[J]. JAMA Oncol, 2016, 2: 1346- 1353.
[4] Calabrese L, Mariette X. The evolving role of the rheumatologist in the management of immune- related adverse events(irAEs) caused by cancer immunotherapy[J]. Ann Rheum Dis, 2018, 77:162- 164.
[5] Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD- 1 versus PD- L1 inhibitors in non- small cell lung cancer: a systematic analysis of the literature[J]. Cancer, 2018, 124: 271- 277.
[6] Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors:consensus recom-mendations from the Society for Immunotherapy of Cancer(SITC)Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5: 95.
[7] 秦叔逵,郭 军,李 进. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南[M]. 北京: 人民卫生出版社,2019
[8] Thompson JA, Schneider BJ, Brahmer J,et al. Management of immunotherapy- related toxicities,version 1. 2019[J]. J Natl Compr Canc Netw, 2019, 17: 255- 289.
[9] Shankar B, Zhang J, Durrant B, et al. Multisystem immune- related adverse events from anti- PD- 1/PD- L1 in patients with lung cancer: incidence, clinical patterns, management, and outcomes[J]. J Clin Oncol, 2019, 37(8 Suppl):84.
[10] Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune- related adverse drug reactions of anti- PD- 1 antibody therapy[J]. Cancer Treat Rev, 2016, 45: 7- 18.
[11] Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma[J]. J Clin Oncol, 2017, 35: 785- 792.
[12] Weber JS, D’Angelo SP, Minor D,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti- CTLA- 4 treatment(CheckMate 037): a randomised, controlled, open- label, phase 3 trial[J]. Lancet Oncol, 2015, 16:375- 384.
[13] Fujisawa Y, Yoshino K, Otsuka A, et al. Fluctuations in routine blood count might signal severe immune- related adverse events in melanoma patients treated with nivolumab[J]. J Dermatol Sci, 2017, 88: 225- 231.
[14] Diehl A, Yarchoan M, Hopkins A, et al. Relationships between lymphocyte counts and treatment- related toxicities and clinical responses in patients with solid tumors treated with PD- 1 check-point inhibitors[J]. Oncotarget, 2017, 8: 114268- 114280.
[15] Noman MZ, Desantis G. Janji B,et al. PD- L1 is a novel direct target of HIF- 1α,and its blockade under hypoxia enhanced MDSC- mediated T cell activation[J]. J Exp Med, 2014, 211: 781- 790.
[16] Zeng Z, Shi F, Zhou L, et al. Upregulation of circulating PD- L1/PD- 1 is associated with poor post- cryoablation prognosis in patients with HBV- related hepatocellular carcinoma[J]. PLoS One, 2011, 6: e23621.
[17] Shi L, Chen L, Wu C, et al. PD- 1 blockade boosts radiofre-quency ablation- elicited adaptive immune responses against tumor[J]. Clin Cancer Res, 2016, 22: 1173- 1184.
[18] Ayaru L, Pereira SP, Alisa A, et al. Unmasking of alpha- fetoprotein- specific CD4+ T cell responses in hepatocellular carcinoma patients undergoing embolization[J]. J Immunol, 2007, 178: 1914- 1922.
[19] Mizukoshi E, Yamashita T, Arai K,et al. Enhancement of tumor- associated antigen- specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J]. Hepatology, 2013, 57:1448- 1457.
[20] 侯思楠,王卫东,钟泽龙,等. 不可逆电穿孔消融术联合PD- 1抑制剂治疗小鼠肝癌效果初步研究[J]. 介入放射学杂志, 2019, 28:454- 458.
[21] Deng L, Liang H, Burnette B, et al. Irradiation and anti- PD- L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124: 687- 695.

备注/Memo

备注/Memo:
(收稿日期:2020- 07- 01)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-01-25